791594-13-3

Usage

Uses

Used in Pharmaceutical Industry:
Cyclopentanecarboxylic acid, 2-(4-bromobenzoyl)-, (1R,2R)is used as a key intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique structure and properties allow for the creation of new molecules with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, Cyclopentanecarboxylic acid, 2-(4-bromobenzoyl)-, (1R,2R)serves as a versatile building block for the development of novel compounds with specific functions and properties. Its chirality and bromine atom contribute to the diversity of synthesized products.
It is important to handle and use Cyclopentanecarboxylic acid, 2-(4-bromobenzoyl)-, (1R,2R)with care due to its potential hazards and toxicity. Proper safety measures should be taken to minimize risks during its production, use, and disposal.

InChI:InChI=1/C13H13BrO3/c14-9-6-4-8(5-7-9)12(15)10-2-1-3-11(10)13(16)17/h4-7,10-11H,1-3H2,(H,16,17)/t10-,11-/m1/s1

Upstream product

• 1019115-10-6 trans-(+/-)-2-(4-bromobenzoyl)cyclopentanecarboxylic acid 
• 1019115-10-6 trans-2-(4-bromobenzoyl)cyclopentanecarboxylic acid 
• 586-75-4 4-chlorobenzoyl chloride 
• 1655-07-8 ethyl 2-oxocyclohexane carboxylate 
• 108-94-1 cyclohexanone 
• 1214270-80-0 2-bromo-6-(4-bromobenzoyl)cyclohexanone 
• 791594-11-1 methyl cis-2-(4-bromobenzoyl)cyclopentanecarboxylate 

Downstream Products

• 959122-11-3 (1R,2R)-2-[[4'-[(phenylamino)carbonyl]amino][1,1'-biphenyl-4-yl]carbonyl]cyclopentanecarboxylic acid 
• 959122-10-2 (1R,2R)-2-({4'-[(anilinocarbonyl)amino]-1,1'-biphenyl-4-yl}carbonyl)cyclopentanecarboxylic acid methyl ester 
• 791594-14-4 methyl (1R,2R)-2-(4-bromobenzoyl)cyclopentanecarboxylate 

Relevant academic research and scientific papers

Process development of a diacyl glycerolacyltransferase-1 inhibitor

A synthesis of a selective diacyl glycerolacyltransferase-1 (DGAT-1) inhibitor, 1, is described. The synthesis illustrates a diketone Favorskii reaction on 9 in place of the more common ketoester variant for generation of the dicarboxycyclopentane core, t

Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme

The present invention relates to compounds of formula (I). wherein R1, R2, R3, R4, R5, R6, m, n, p and q are defined herein Pharmaceutical compositions and methods for treating DGAT-1 relat

Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor

A highly potent and selective DGAT-1 inhibitor was identified and used in rodent models of obesity and postprandial chylomicron excursion to validate DGAT-1 inhibition as a novel approach for the treatment of metabolic diseases. Specifically, compound 4a conferred weight loss and a reduction in liver triglycerides when dosed chronically in DIO mice and depleted serum triglycerides following a lipid challenge in a dose-dependent manner, thus, reproducing major phenotypical characteristics of DGAT-1-/- mice.

INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME

The present invention relates to compounds of formula (I) wherein R1, R3, X, Q, Z, A, D, m, and n are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.